BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:27 PM
 | 
Jun 08, 2010
 |  BC Extra  |  Clinical News

NovoCure reports NovoTTF data

NovoCure Ltd.'s NovoTTF monotherapy missed the primary endpoint of significantly improving overall survival (OS) in the intent-to-treat (ITT) population vs. best standard chemotherapy (BSC) in a Phase III trial to treat recurrent, late-stage glioblastoma multiforme (GBM) (6.6 vs. 6...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >